Liquidia Corp Ordinary Shares LQDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LQDA is a good fit for your portfolio.
News
-
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
-
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling
-
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
-
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
-
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
-
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
-
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
-
Liquidia Corporation Announces Updates to Operations Leadership
Trading Information
- Previous Close Price
- $13.69
- Day Range
- $13.48–13.91
- 52-Week Range
- $5.72–16.99
- Bid/Ask
- $13.51 / $13.53
- Market Cap
- $1.03 Bil
- Volume/Avg
- 263,836 / 884,084
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 55.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 145
- Website
- https://www.liquidia.com
Comparables
Valuation
|
Metric
|
LQDA
|
HLVX
|
ICVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 21.71 | 2.52 | 3.30 |
Price/Sales | 55.60 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
LQDA
HLVX
ICVX
Financial Strength
|
Metric
|
LQDA
|
HLVX
|
ICVX
|
|---|---|---|---|
Quick Ratio | 4.73 | 10.37 | 17.59 |
Current Ratio | 4.85 | 10.62 | 18.06 |
Interest Coverage | −12.07 | −54.72 | — |
Quick Ratio
LQDA
HLVX
ICVX
Profitability
|
Metric
|
LQDA
|
HLVX
|
ICVX
|
|---|---|---|---|
Return on Assets (Normalized) | −54.21% | −34.03% | −29.30% |
Return on Equity (Normalized) | −100.76% | −42.52% | −31.87% |
Return on Invested Capital (Normalized) | −85.99% | −38.62% | −34.69% |
Return on Assets
LQDA
HLVX
ICVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yjyfdfsbf | Zlzq | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dffsmszl | Lqsvnp | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vrkvhfnm | Mvyncx | $98.6 Bil | |
MRNA
| Moderna Inc | Cwslfzmt | Ppv | $41.0 Bil | |
ARGX
| argenx SE ADR | Rkkxzbgk | Trh | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Ddpxykyf | Pkwq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ygrvhkdw | Xmtfvz | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pczgvgm | Jdwpcd | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cdcfnsyjf | Zcnzqy | $12.6 Bil | |
INCY
| Incyte Corp | Bnzsrhf | Fzqbqs | $12.0 Bil |